|
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next
|
|
| |
|
Feb '07
|
|
Drugs for HIV Dementia
| |
In the early years of the epidemic, AIDS dementia caused some with the disease to degenerate to the level of end-stage Alzheimer's patients; death typically followed within six months.
With today's treatments, the often-unpredictable condition known as neuroAIDS is more subtle and appears four or more years before death. |
|
|
Feb '07
|
|
FDA Approves New Lipoatrophy Treatment
| |
A 100-patient study found statistically significant improvements in cheek thickness through six months in HIV-infected patients with facial lipoatrophy; the majority of patients received
a total of three injections during the study period: one at baseline, a second at one month, and a touch-up at six months. |
|
|
Feb '07
|
|
Fuzeon Shows Combo Benefits
| |
Up to 95 percent of patients treated with the fusion inhibitor Fuzeon in combination with an antiretroviral can achieve undetectable HIV levels, Swiss drug maker Roche said recently. |
|
|
Feb '07
|
|
HIV or Antiretrovirals?
| |
The researchers found and elucidated the means by which a protein within HIV can trigger a reduction in a patient's HDL cholesterol levels. "The data support the shift away from a
paradigm of delaying or stopping [antiretroviral therapy] to reduce the risk of cardiovascular disease," the researchers write.
from
theBodyPro.com
|
|
|
Jan '07
|
|
Treated Poz Waists No Bigger
| |
Researchers used circumference measurements to track men's hip
and waist size over a four-year period. Their findings show that HIV-infected men on HAART were no more likely to gain waist fat than HIV-uninfected men. |
|
|
Jan '07
|
|
Green Tea Shows HIV Promise
| |
In a new study, scientists report that test-tube experiments show a component in green tea blocks the ability of HIV to invade and destroy cells of the immune system. |
|
|
Jan '07
|
|
New Reyataz Approval
| |
New Jersey-based Bristol-Myers Squibb said the Food and Drug Administration has approved its single-capsule formulation of Reyataz as part of combination therapy for HIV infection. |
|
|
Dec '06
|
|
Using AIDS to Fight AIDS
| |
It is still not certain whether the approach could be useful only in infected patients, or someday prove to be prophylactic for
HIV-negative individuals. |
|
|
Dec '06
|
|
Wringing Fat Out of Blood
| |
CVD risk data from the largest and longest studied cohorts in the setting of HIV infection suggest that cumulative years of exposure to combination drug therapy increases the risk of myocardial infarction
and stroke. |
|
|
Dec '06
|
|
Three Die on Waiting List
| |
South Carolina's Health Department has confirmed that three people with HIV/AIDS died while on a waiting list for the State AIDS Drug Assistance Program (ADAP). |
|
|
Nov '06
|
|
Testing for Prisoners?
| |
Mandatory testing has long raised concerns among civil libertarians and other activists. Although Waters's bill would allow prisoners to refuse to undergo testing, she acknowledged her proposal might alarm some advocates. |
|
|
Nov '06
|
|
Integrase Inhibitor Promise
| |
The integrase inhibitors "really look fantastic, with very few side effects," said Dr. Mark Wainberg, a McGill University professor and conference co-chair. |
|
|
Nov '06
|
|
One in 10 Straight Men on the 'Down-Low'?
| |
The study is a wake-up call for doctors not to make assumptions about their
patients' sexual practices, or rely upon self-reported identities. |
|
|
Nov '06
|
|
Free Condoms in Campus Bathrooms
| |
Last month, officials of the University of Missouri-Columbia announced the school would become the first in the Big 12 Conference to offer free condoms in residence-hall bathrooms. |
|
|
Oct '06
|
|
Toronto: AIDS Refugees
| |
An Eritrean seeking refugee status after attending last month's 16th International AIDS Conference in Toronto is basing his claim to stay in Canada on persecution by Eritrean authorities. |
|
|
Oct '06
|
|
Vietnam: Condoms Grounds for Arrest
| |
Police in the district have reiterated that condom possession is still grounds for arrest. |
|
|
Oct '06
|
|
Hydrogen Peroxide: Warning
| |
"No one has presented any evidence that hydrogen peroxide taken internally has any medical value," Dr. Steven Galson, director of FDA's Center for Drug Evaluation and Research, said in a statement. "In fact,
consuming hydrogen peroxide in the manner touted by these Web sites could lead to tragic results." |
|
|
Oct '06
|
|
India: Legalize Gay Sex?
| |
Though few persons are actually prosecuted under the code, AIDS activists say the police use it to
harass gays. "Section 377 can adversely contribute to pushing the infection underground, make risky sexual practices go unnoticed and unaddressed," NACO said in its affidavit to the court. |
|
|
Sep '06
|
|
Drugs Still Effective After 10 Years
| |
A recent study says HIV/AIDS combination therapy drugs remain effective ten years after their introduction, but many patients are not put on them soon enough. |
|
|
Sep '06
|
|
Once a Day Pill?
| |
The Food and Drug Administration has approve a new pill that combines three of the most widely prescribed HIV drugs in the United States into a once-daily pill. |
|
|
Sep '06
|
|
Africans Better at Taking AIDS Drugs
| |
A new study examining data from almost 30,000 HIV patients found 77 percent treatment-adherence among African patients versus 59 percent adherence among North American patients. |
|
|
Sep '06
|
|
Drugs Reach One in Five
| |
A CDC study released earlier this month said only one in five HIV patients in poor and middle-income countries receives drug therapy, despite a 200 percent rise in the number of patients in treatment between 2003
and 2005. |
|
|
Sep '06
|
|
Trials for Drug That Leaves HIV Defenseless
| |
Recent in-vitro experiments of the drug PA-457 potentially indicate a new class of HIV maturation inhibitor drugs that could be used to overcome HIV that is resistant to current treatments. |
|
|
Sep '06
|
|
US Approves TMC114
| |
The FDA has granted approval for TMC114 (darunavir, Prezista), a protease inhibitor indicated for the treatment of multidrug-resistant, HIV-infected patients. |
|
|
Sep '06
|
|
HIV Drug Tied to Eight Deaths
| |
The US Food and Drug Administration (FDA) and Boehringer Ingelheim have reported that 13 patients taking the company's HIV drug Aptivus had bleeding in the brain, and eight of them died. |
|
|
Aug '06
|
|
Sustiva: No Added Depression Risk?
| |
Patients who receive a HAART regimen containing
efavirenz (Sustiva, Stocrin) are at no greater risk for
developing depression than patients who receive a
protease inhibitor (PI)-based regimen. |
|
|
Aug '06
|
|
IL-2 No Help in Treatment Interruptions
| |
Recent research, most notably the SMART study,
has highlighted the potential risks of CD4-guided
HIV treatment interruptions. |
|
|
Aug '06
|
|
HCV Does Not Accelerate HIV Progression or Impede Treatment
| |
Although HIV is known to increase the severity of
hepatitis C (HCV) infection, HCV does not have the
same impact on HIV, according to the results of a
massive study. |
|
|
Aug '06
|
|
Safety Concerns Cast Shadow over Novel Class of HIV Drugs
| |
A new class of experimental HIV drugs, CCR5
receptor antagonists, is raising safety concerns. |
|
|
Aug '06
|
|
HIV Docs and Patients: Different Perceptions
| |
A nationwide survey of HIV-infected patients and
physicians has found that the two groups often
hold divergent views on HIV care. |
|
|
|
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next
|
Advertise with us
Subscriptions
Contact us
Site map
Translate
